danicopan   Click here for help

GtoPdb Ligand ID: 11988

Synonyms: ACH-4471 | ACH4471
Compound class: Synthetic organic
Comment: Danicopan (ACH-4471) is an oral, direct inhibitor of the protease activity of complement factor D [1,4-5], which is a component of the alternative complement pathway. It was originally developed for potential to control complement-mediated intravascular hemolysis and prevent C3-mediated extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria [3].

COVID-19: Danicoplan is being included in the ACTIV-5 platform trial NCT04988035 that is designed to identify promising agents as potential COVID-19 therapeutics that are suitable for progression to more definitive studies. It is initially being tested as a monotherapy and in combination with remdesivir in hospitalised COVID-19 patients.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 122.97
Molecular weight 579.1
XLogP 2.88
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES F[C@H]1CN([C@@H](C1)C(=O)Nc1cccc(n1)Br)C(=O)Cn1nc(c2c1ccc(c2)c1cnc(nc1)C)C(=O)C
Isomeric SMILES Cc1ncc(cn1)c1cc2c(cc1)n(nc2C(=O)C)CC(=O)N1C[C@@H](C[C@H]1C(=O)Nc1nc(ccc1)Br)F
InChI InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1
No information available.
Summary of Clinical Use Click here for help
Danicopan is in clinical trial in patients with the complement-mediated disease paroxysmal nocturnal hemoglobinuria.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03053102 Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2 Interventional Alexion Pharmaceuticals 3
NCT03472885 Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Phase 2 Interventional Alexion Pharmaceuticals 2
NCT04988035 ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 Phase 2 Interventional National Institute of Allergy and Infectious Diseases (NIAID)